AIA Group Ltd Acquires 7,547 Shares of Illumina, Inc. (NASDAQ:ILMN)

AIA Group Ltd increased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 13.1% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 65,214 shares of the life sciences company’s stock after buying an additional 7,547 shares during the period. AIA Group Ltd’s holdings in Illumina were worth $8,505,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of ILMN. Versant Capital Management Inc raised its stake in Illumina by 292.9% in the second quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock worth $34,000 after buying an additional 246 shares in the last quarter. Industrial Alliance Investment Management Inc. acquired a new position in shares of Illumina during the second quarter worth $34,000. Massmutual Trust Co. FSB ADV increased its position in shares of Illumina by 65.1% during the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after purchasing an additional 168 shares in the last quarter. Itau Unibanco Holding S.A. acquired a new position in shares of Illumina during the second quarter worth $61,000. Finally, Mizuho Securities Co. Ltd. acquired a new position in shares of Illumina during the second quarter worth $63,000. Institutional investors own 89.42% of the company’s stock.

Illumina Stock Up 2.2 %

ILMN stock opened at $155.15 on Friday. Illumina, Inc. has a one year low of $89.00 and a one year high of $156.66. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.86 and a current ratio of 1.11. The firm’s fifty day moving average is $137.27 and its 200 day moving average is $123.12. The firm has a market cap of $24.72 billion, a PE ratio of -15.58 and a beta of 1.13.

Illumina (NASDAQ:ILMN) last posted its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 6.36%. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same period in the prior year, the company posted $0.33 EPS. The company’s revenue for the quarter was down 3.5% on a year-over-year basis. On average, research analysts forecast that Illumina, Inc. will post 3.62 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on ILMN shares. Scotiabank reduced their price target on Illumina from $176.00 to $164.00 and set a “sector outperform” rating on the stock in a research report on Thursday, August 15th. JPMorgan Chase & Co. upped their price target on Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research report on Tuesday. Argus raised Illumina from a “hold” rating to a “buy” rating and set a $150.00 price target on the stock in a research report on Wednesday, August 28th. Royal Bank of Canada upped their price target on Illumina from $252.00 to $254.00 and gave the stock an “outperform” rating in a research report on Tuesday. Finally, HSBC raised Illumina from a “hold” rating to a “buy” rating and set a $180.00 target price on the stock in a research report on Thursday, October 17th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Illumina presently has an average rating of “Moderate Buy” and a consensus target price of $162.18.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.